At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 182 enrolled
Drug / intervention
CM-AT +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Randomized Double Blind Placebo Controlled Trial of CM-AT in Children With Autism
In Brief
A Phase 3 clinical trial evaluating CM-AT and Placebo for Autism. Completed, enrolled 182 participants across 19 sites.
Detailed Summary
The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2009
Enrollment StartMay 2009
Primary CompletionJun 2011
Study CompletionSep 2011
TodayJul 2026
First PostedApr 15, 2009
Enrollment StartMay 1, 2009
Primary CompletionJun 1, 2011
Study CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.2 years ago
Interventions
CM-ATdrug
Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
Placebodrug
Single unit dose powder of non-active substance administered 3 times per day for 90 days